Table S1.
Summary of clinical data from patients and results of LMP1 surface-enhanced Raman scattering and LMP1 immunohistochemistry staining, as well as EBER-ISH
| Number | Gender | Age | Pathological type | Site | SERS | ISH | IHC |
|---|---|---|---|---|---|---|---|
| P1 | Male | 61 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P2 | Male | 51 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P3 | Male | 45 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P4 | Male | 55 | WHO type III | Cervical lymph node | Positive | Positive | Negative |
| P5 | Male | 50 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P6 | Male | 52 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P7 | Male | 46 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P8 | Female | 38 | WHO type III | Cervical lymph node | Negative | Positive | Positive |
| P9 | Female | 32 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P10 | Male | 57 | WHO type III | Cervical lymph node | Positive | Positive | Negative |
| P11 | Male | 55 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P12 | Male | 44 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P13 | Male | 44 | WHO type III | Cervical lymph node | Positive | Positive | Negative |
| P14 | Male | 41 | WHO type III | Cervical lymph node | Positive | Positive | Negative |
| P15 | Male | 57 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P16 | Male | 46 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P17 | Male | 49 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P18 | Male | 62 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P19 | Female | 48 | WHO type III | Cervical lymph node | Positive | Positive | Negative |
| P20 | Male | 39 | WHO type III | Cervical lymph node | Positive | Positive | Negative |
| P21 | Male | 56 | WHO type III | Cervical lymph node | Positive | Positive | Positive |
| P22 | Male | 59 | WHO type II | Nasopharynx | Positive | Positive | Negative |
| P23 | Male | 58 | WHO type III | Nasopharynx | Positive | Positive | Positive |
| P24 | Male | 53 | WHO type III | Nasopharynx | Positive | Positive | Positive |
| P25 | Male | 64 | WHO type III | Nasopharynx | Positive | Positive | Negative |
| P26 | Male | 66 | WHO type III | Nasopharynx | Positive | Positive | Positive |
| P27 | Male | 45 | WHO type III | Nasopharynx | Positive | Positive | Negative |
| P28 | Male | 37 | WHO type III | Nasopharynx | Positive | Positive | Negative |
| P29 | Male | 44 | WHO type III | Nasopharynx | Positive | Positive | Positive |
| P30 | Male | 65 | WHO type III | Nasopharynx | Positive | Positive | Positive |
| P31 | Female | 56 | WHO type III | Nasopharynx | Positive | Positive | Negative |
| P32 | Male | 47 | WHO type III | Nasopharynx | Positive | Positive | Negative |
| P33 | Male | 57 | WHO type III | Nasopharynx | Positive | Positive | Positive |
| P34 | Male | 45 | WHO type III | Nasopharynx | Positive | Positive | Positive |
| Average age | 50.7 ± 8.6 years | ||||||
| Gender ratio (male/female) | 30/4 | ||||||
| Healthy subjects (n = 20) | 16 male/4 female | 42.0 ± 14.9 | Normal nasopharyngeal epithelial tissues | All from nasopharynx | All are negative | All are negative | All are negative |
Note: WHO type III is non-keratinizing undifferentiated form of NPC; WHO type II is non-keratinizing differentiated form of NPC.
Abbreviations: EBV, Epstein–Barr virus; EBER, EBV encoded small RNA; IHC, immunohistochemistry; ISH, in situ hybridization; LMP1, latent membrane protein 1; SERS, surface-enhanced Raman scattering; WHO, World Health Organization.